Peregrine Pharmaceuticals (NASDAQ:PPHM)
CAPS Rating:
A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.
RSS Headlines
Fool UK
Recs
Not much insider trading lately but the most recent was a buy by a director. Charts look very bottomy as well.
No insider sales for TWO YEARS!